Novel receptor antagonists welcome a new era in endothelin biology.
Douglas
S A
SA
Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406.
Meek
T D
TD
Ohlstein
E H
EH
D000595:Amino Acid Sequence; D000818:Animals; D001161:Arteriosclerosis / Q000188:drug therapy; D016282:Aspartic Acid Endopeptidases / Q000235:genetics; D016466:CHO Cells; D002561:Cerebrovascular Disorders / Q000188:drug therapy; D006224:Cricetinae; D065128:Endothelin Receptor Antagonists; D000072396:Endothelin-Converting Enzymes; D016232:Endothelins / Q000235:genetics / Q000378:metabolism*; D015971:Gene Expression Regulation, Enzymologic / Q000235:genetics; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D007674:Kidney Diseases / Q000188:drug therapy; D008666:Metalloendopeptidases / Q000235:genetics; D008969:Molecular Sequence Data; D017466:Receptors, Endothelin / Q000145:classification / Q000502:physiology; D013329:Structure-Activity Relationship
D065128:Endothelin Receptor Antagonists; D016232:Endothelins; D017466:Receptors, Endothelin; D016282:Aspartic Acid Endopeptidases; D008666:Metalloendopeptidases; D000072396:Endothelin-Converting Enzymes